Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) closed the day trading at $33.84 down -6.55% from the previous closing price of $36.21. In other words, the price has decreased by -$6.55 from its previous closing price. On the day, 0.99 million shares were traded. RARE stock price reached its highest trading level at $36.06 during the session, while it also had its lowest trading level at $33.69.
Ratios:
For a better understanding of RARE, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.24 and its Current Ratio is at 2.37. In the meantime, Its Debt-to-Equity ratio is 3.56 whereas as Long-Term Debt/Eq ratio is at 3.33.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on June 06, 2024, Upgraded its rating to Buy and sets its target price to $67 from $56 previously.
On April 22, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $77.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $72.Wells Fargo initiated its Overweight rating on December 08, 2023, with a $72 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 06 ’25 when Horn Howard sold 1,785 shares for $40.40 per share. The transaction valued at 72,114 led to the insider holds 106,169 shares of the business.
Kassberg Thomas Richard sold 6,028 shares of RARE for $253,779 on Mar 03 ’25. The CBO & EVP now owns 265,238 shares after completing the transaction at $42.10 per share. On Mar 03 ’25, another insider, Parschauer Karah Herdman, who serves as the EVP and Chief Legal Officer of the company, sold 12,846 shares for $42.10 each. As a result, the insider received 540,817 and left with 75,287 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 3177565696 and an Enterprise Value of 3437223168. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.59 while its Price-to-Book (P/B) ratio in mrq is 12.25. Its current Enterprise Value per Revenue stands at 6.135 whereas that against EBITDA is -6.869.
Stock Price History:
The Beta on a monthly basis for RARE is 0.61, which has changed by -0.28122348 over the last 52 weeks, in comparison to a change of 0.08089435 over the same period for the S&P500. Over the past 52 weeks, RARE has reached a high of $60.37, while it has fallen to a 52-week low of $35.53. The 50-Day Moving Average of the stock is -18.24%, while the 200-Day Moving Average is calculated to be -28.03%.
Shares Statistics:
Over the past 3-months, RARE traded about 824.62K shares per day on average, while over the past 10 days, RARE traded about 772990 shares per day. A total of 92.41M shares are outstanding, with a floating share count of 86.26M. Insiders hold about 6.75% of the company’s shares, while institutions hold 95.06% stake in the company. Shares short for RARE as of 1741910400 were 4813611 with a Short Ratio of 5.84, compared to 1739491200 on 4284000. Therefore, it implies a Short% of Shares Outstanding of 4813611 and a Short% of Float of 5.9699997.
